Institutional sentiment in the MNKD stock forecast shows an uptick, with hedge fund holdings rising 4% quarter-over-quarter. This data points to growing confidence in MannKind’s revenue trajectory from Afrezza sales. MannKind already has institutions on the share registry. Indeed, they own a respectable stake in the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at MannKind's earnings history below. Of course, the future is what really matters. The most recent analyst rating on (MNKD) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on MannKind stock, see the MNKD Stock Forecast page . Short interest in MNKD, currently at 7.8% of float, has dipped slightly, which aligns with the MNKD stock forecast narrative of reduced bearish pressure as biotech valuations stabilize.
